The FDA banned the use of red dye No. 3 in foods and medicines sold in the U.S. because it has been shown to cause cancer in ...

The proposed "Nutrition info box" would show customers whether products have low, medium or high levels of saturated fat, ...

Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...

A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® ...

The key lies in adopting proven strategies that focus on sustainable lifestyle changes rather than quick fixes. A well-balanced diet combined with regular exercise and stress management are essential ...

After delay, Roche's Tecentriq Hybreza wins first FDA approval for a subcutaneous PD-L1 drug Opdivo Qvantig’s average administration time of less than five minutes was observed in the Checkmate ...

Hikma recently received the Food and Drug Administration’s permission ... older with Type 2 diabetes as an adjunct to diet and exercise. The FDA approved the first generic in this class of ...

The drug has been specifically approved for adults with moderate-to-severe obstructive sleep apnea and obesity. Its use is recommended alongside increased exercise and a lower-calorie diet.

For many people, the end of the year is a mad rush to wrap things up before the holidays, and so it was for the FDA. Notable regulatory decisions include the first drug approval for a prevalent ...

Neffy for severe allergic reactions and Dupixent for chronic obstructive pulmonary disease (COPD), which all gained FDA approval this year. These medications are "slated to make a big clinical ...